Topics:

WSJ: Pfizer animal health IPO could happen next month

Sources say Pfizer figures it gets more this way than an outright sale
Tools
Pfizer's animal health unit may be worth $20 billion--courtesy of Pfizer

Pfizer's animal health unit may be worth $20 billion, and that is the conundrum.

With the value having inflated beyond the reach of potential buyers, Pfizer ($PFE) has decided it must move forward with an public stock offering instead of a sale, perhaps as early as next month, sources tell The Wall Street Journal.

The drugmaking behemoth has decided an IPO of about 20% of Zoetis could bring roughly $4 billion and is the best way to get the most value out the unit, The Wall Street Journal says. The unit earned about $3.1 billion in the first 9 months of 2012. Pfizer will eventually spin off the remaining 80% tax-free to shareholders.

The company last year decided to unload the division as part of its plan to help replace revenue lost when its cholesterol-lowering Lipitor, the world's best-selling drug, was hit by generic competition. There had been rumors that Bayer or Novartis ($NVS) might be interested in buying it but those have cooled more recently.

There have been other deals in animal health lately. Germany's Bayer in September agreed to pick up the much smaller animal health unit of Teva Pharmaceutical Industries ($TEVA) for $145 million. That was announced a couple of days after up-and-coming generic drugmaker Perrigo ($PRGO) announced that it was buying Sergeant's Pet Care Products for $285 million.

- here's The Wall Street Journal's story
- get more from Reuters

Related Articles:
It's official: Pfizer files its animal-health IPO
Pfizer nears animal health IPO as cost-cutting boosts profits
Pfizer readies documents for animal health IPO
Bayer picks up Teva's animal health biz for $145M